ERBB2 and breast carcinoma: In HER2-positive cell lines of breast cancer, each cell line showed a distinct adaptive response to the HER2 inhibitor Lapatinib by activating a unique set of compensatory kinases through epigenetic means, underscoring the difficulty of identifying effective combinations against widely heterogeneous tumors (32).